TOBI tobramycin solution for inhalation: Began Study

PGNS subsidiary PathoGenesis Ltd. began an open-label study in 120 patients in the U.K. comparing 300 mg of TOBI twice daily in combination with standard CF care to 80 mg of Pharmax's Colomycin antib...